Online inquiry

IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2034MR)

This product GTTS-WQ2034MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2034MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11949MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ1784MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ778MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ2079MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ4278MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ10539MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ12354MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ11327MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-524
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW